Compare CHOW & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHOW | LEXX |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | Hong Kong | Canada |
| Employees | 17 | 7 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 16.5M |
| IPO Year | N/A | N/A |
| Metric | CHOW | LEXX |
|---|---|---|
| Price | $0.38 | $0.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | ★ 10.2M | 65.9K |
| Earning Date | 06-17-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $601.47 |
| P/E Ratio | $10.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.46 |
| 52 Week High | $12.05 | $1.55 |
| Indicator | CHOW | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 42.75 |
| Support Level | $0.34 | $0.46 |
| Resistance Level | $0.52 | $0.70 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 4.18 | 25.08 |
ChowChow Cloud International Holdings Ltd provides one-stop cloud solutions that support companies across the IT industry value chain throughout their entire cloud transformation journey, from consulting, deployment, and migration to cloud environment building and management. Its business comprises (i) digital transformation consulting services consisting of cloud suitability assessment, (ii) professional IT services comprising capabilities designed to facilitate seamless cloud integration and digital transformation, (iii) AI-powered proactive cloud managed services covering all aspects of day-to-day cloud maintenance and support, and (iv) IT infrastructure solutions covering on-premise private cloud setups and public cloud integrations, including infrastructure applications.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.